What is the rationale for testing ASA404 treatment in patients with NSCLC?
Although several novel drugs have been introduced recently, there is still an unmet need for a more effective second-line treatment for NSCLC. ASA404 has a unique mode of action and has shown synergistic activity in combination with taxanes. In a phase lb/ll trial of ASA404 for the first-line treatment of patients with stage IIIb or stage IV NSCLC, presented at the 2006 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, the addition of ASA404 to paclitaxel and carboplatin increased median survival by 5.2 months.
